[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 20, 1965

Risks vs Benefits in Rheumatology: The Current Status of Drug Therapy

JAMA. 1965;194(12):23-27. doi:10.1001/jama.1965.03090250083045

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

Drug therapy for the rheumatoid patient—the selection of an agent and course of treatment—is often a difficult and frustrating task for the physician.

"Nowhere have the problems involved in the selection of a therapeutic agent been more apparent than in the chronic rheumatoid disorders," said Nathan J. Zvaifler, MD. "Lacking a definite etiology, their therapy has frequently been pragmatic or symptomatic."

Added to the unpredictable and varying course of disease is a further complication arising from the nature of the available therapeutic agents: virtually every drug useful in treatment of rheumatoid disease is potentially toxic.

Effects Noted  These toxic effects include gastrointestinal bleeding from salicylates, renal papillary necrosis from phenacetin, blood dyscrasias and peptic ulcers from phenylbutazone, dermatitis and renal complications from gold salts, retinal damage from the antimalarials, purpura, peptic ulcer and osteoporosis from corticosteroids, and gastrointestinal and cerebral complications from the use of indomethacin.Improvement is possible in

First Page Preview View Large
First page PDF preview
First page PDF preview
×